Feasibility Study of a Mobile Health App for Symptom Monitoring in People With Chronic Pancreatitis (SmartCP)

August 14, 2023 updated by: Sinead Duggan, University of Dublin, Trinity College

Feasibility Study of a Mobile Health App for Symptom Monitoring in People With Chronic Pancreatitis: The SmartCP Study

Patients with chronic pancreatitis suffer from constant debilitating symptoms. They have complex needs and require specialist, multi-disciplinary care. The investigators have developed a mobile phone app for patients with chronic pancreatitis, called the SmartCP app - the first app of its kind for this patient group.

What is SmartCP? SmartCP is an app that allows patients to log daily symptoms, diet, and physical activity for review at clinic. It creates a red-alert for action if there are worsening symptoms. A Monthly-Check-In feature looks for symptoms of new diabetes or pancreatic cancer. SmartCP provides education on every aspect of pancreatitis, as well as contact information for the clinical team and for important pancreatitis resources. To develop SmartCP, the investigators established a multidisciplinary steering committee.

The study The investigators aim to conduct a feasibility study to determine if the SmartCP app is feasible in the management of patients with chronic pancreatitis, complementing current specialist healthcare. Specifically, they will investigate acceptability, retention, incidents, resources, app user statistics, as well as investigating the occurrence of crisis events, symptoms, escalating symptoms, new diagnoses of diabetes or pancreatic cancer, and the use of communication and education features.

Study Overview

Status

Not yet recruiting

Intervention / Treatment

Detailed Description

Background and rationale Chronic pancreatitis is an inherently complex disease requiring coordinated, multidisciplinary care. Patients suffer from constant, distressing, adverse symptoms including abdominal pain, steatorrhoea, bloating, wind, cramping, and fatigue - making it difficult to eat a normal or sufficient diet. They develop vitamin deficiencies, osteoporosis, and a difficult-to-manage diabetes subgroup (type 3c diabetes). There is no effective medical/surgical treatment, and the disease is progressive and incurable. The mainstay of treatment is diet, supplementation, and pancreatic enzyme replacement therapy- which helps patients to digest and absorb their food, alleviating symptoms somewhat. Contrary to perceptions, half of patients (or fewer) have an alcohol related aetiology.

The investigators run several out-patient clinics for chronic pancreatitis including medical-led, nurse-specialist led, and type 3c diabetes clinics. A nurse specialist deal with 3-5 crisis phonically daily, each lasting up to 30mins. Patients have frequent urgent clinic attendance, A&E, and hospital admissions.

What is the intervention? A steering group designed and developed the SmartCP mobile phone app during 2022 with the support of a government innovation grant. SmartCP consists of a symptom tracker, diet/physical activity log, alert system for escalating symptoms, quality of life assessment, red-flag alerts for diabetes/pancreatic cancer, educational content, push notifications and messaging function.

Overall aim of the study To conduct a study to determine if SmartCP is feasible in the management patients with chronic pancreatitis, complementing current specialist clinical care.

Design A single-arm, unblinded, feasibility study, with an uncontrolled, within-group baseline and post-intervention (16-week) design, with an embedded quantitative and qualitative process evaluation. Participants will receive the intervention for 16 weeks, supplementing usual clinical practice.

Study Type

Interventional

Enrollment (Estimated)

30

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Dublin, Ireland
        • University of Dublin, Trinity College

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Child
  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Reside in Ireland
  • Can read/write in English
  • Have daily access to compatible smartphone
  • Have daily access to home internet

Exclusion Criteria:

  • Reside outside Ireland
  • Acutely unwell
  • Has multi-morbidity
  • Is current inpatient
  • Has prognosis <6months
  • Has pancreatic cancer
  • Is <18 years
  • Has no access to compatible smartphone
  • Has no access to home internet
  • Cannot read/write in English
  • Is unwilling/unable to provide informed consent

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Other
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: SmartCP app
The SmartCP app is provided to patients to assist in the management of chronic pancreatitis for 16 weeks
As described
Other Names:
  • Co-designed with MyPatientSpace https://www.mypatientspace.com

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Feasibility: Recruitment
Time Frame: 16 weeks
The number of participants that are recruited versus the number eligible for recruitment
16 weeks
Feasibility: Acceptability
Time Frame: 16 weeks
Acceptability of intervention (Telehealth Usability Questionnaire; 21 questions with scale of 1 to 7 for each question, with higher scores indicating more positive results)
16 weeks
Feasibility: Retention
Time Frame: 16 weeks
Retention: Number of participant who continue to use SmartCP by the end of the intervention
16 weeks
Feasibility: Incidents
Time Frame: 16 weeks
Number of adverse events reported by patients
16 weeks
Feasibility: User statistics
Time Frame: 16 weeks
Minutes per day spent on the app during the intervention period
16 weeks
Feasibility: User statistics
Time Frame: 16 weeks
Number per day of unique log-ins to the app during the intervention period
16 weeks

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Occurrence of crisis events: Crisis phone-calls
Time Frame: 16 weeks
Number of crisis phone-calls per day to Tallaght University Hospital Advanced Nurse Practitioner
16 weeks
Occurrence of crisis events: Accident & Emergency
Time Frame: 16 weeks
Number of attendances per week at Accident & Emergency Room in any hospital
16 weeks
Occurrence of crisis events: Urgent clinic
Time Frame: 16 weeks
Number of urgent out-patient clinic attendances per week in Tallaght university Hospital
16 weeks
Symptoms: The nature and frequency of each symptom recorded using the daily symptoms tracker while using the app
Time Frame: 16 weeks
Recording of tiredness or lack of energy, steatorrhoea, loss of appetite, nausea, vomiting, dyspepsia, bloating or stomach distention, excess wind or flatulence - all according to the following scale: none, mild, moderate, severe
16 weeks
Symptoms: Number of Alerts created by the app
Time Frame: 16 weeks
The number of alerts created by the app in response to escalating symptoms requiring a phone-call or clinic attendance
16 weeks
Symptoms: Number of Red-Flag alerts created by the app
Time Frame: 16 weeks
The number of Red-flag alerts for possible new pancreatic cancer symptoms; red-flag alert for possible new diabetes symptoms
16 weeks
Quality of life (QoL): Short Form-12
Time Frame: 16 weeks
Change in QoL scores measured by Short Form-12; Scores range from 0-100, with higher scores indicating better QoL
16 weeks
Quality of life (QoL): EQ-5D
Time Frame: 16 weeks
Changes in QoL measured by EQ-5D, a self-reported questionnaire that describes a respondent's health using a descriptive system comprised of five items, each representing a different health dimension (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression). For each dimension, respondents state whether they have no problems, slight problems, moderate problems, severe problems, or are unable to perform the activity. Score range is 0-100. Higher scores indicate better QoL
16 weeks
Hospitalisation: Number of admissions
Time Frame: 16 weeks
Number of admissions to any hospital during the intervention period
16 weeks
Hospitalisation: Length of hospital stay
Time Frame: 16 weeks
Length of hospital stay at any hospital during the intervention period
16 weeks
Use of communications features: Number of times per week patients use app communications features
Time Frame: 16 weeks
Number of times per week that patients use the communication features on app (messaging the Advanced Nurse Practitioner via the app with a query)
16 weeks
Use of educational features: Number of times per week patients view app educational/informational features
Time Frame: 16 weeks
Number of times per week patients view various videos, graphic videos, read educational texts, click on new education features provided
16 weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

November 1, 2023

Primary Completion (Estimated)

October 1, 2024

Study Completion (Estimated)

October 1, 2025

Study Registration Dates

First Submitted

May 8, 2023

First Submitted That Met QC Criteria

June 2, 2023

First Posted (Actual)

June 12, 2023

Study Record Updates

Last Update Posted (Actual)

August 18, 2023

Last Update Submitted That Met QC Criteria

August 14, 2023

Last Verified

August 1, 2023

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

IPD Plan Description

To be decided

IPD Sharing Time Frame

After publication and for the statutory GDPR period

IPD Sharing Supporting Information Type

  • STUDY_PROTOCOL
  • CSR

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Chronic Pancreatitis

Clinical Trials on SmartCP (mobile phone app)

Subscribe